AR081991A2 - FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS - Google Patents

FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Info

Publication number
AR081991A2
AR081991A2 ARP110102193A ARP110102193A AR081991A2 AR 081991 A2 AR081991 A2 AR 081991A2 AR P110102193 A ARP110102193 A AR P110102193A AR P110102193 A ARP110102193 A AR P110102193A AR 081991 A2 AR081991 A2 AR 081991A2
Authority
AR
Argentina
Prior art keywords
production
rifaximin
crystallization
rifaximine
processes
Prior art date
Application number
ARP110102193A
Other languages
English (en)
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081991(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of AR081991A2 publication Critical patent/AR081991A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Forma cristalina polimórfica del antibiótico rifaximina (INN) denominadas rifaximina b que presenta un contenido de agua mayor que un 4,5% y produce un difractograma de polvo por rayos X que presenta picos en valores de ángulos de difracción 2q de 5,4º; 6,4º; 7,0º; 7,8º; 9,0º; 10,4º; 13,1º; 14,4º; 17,1º; 17,9º; 18,3º; 20,9º. Esta forma es de utilidad en la producción de preparaciones medicinales para uso por vía oral y tópica y se pueden obtener por medio de un proceso de cristalización llevado a cabo por disolución en caliente de la rifaximina cruda en alcohol etílico y por cristalización del producto mediante la adición de agua a una temperatura determinada y por un periodo de tiempo determinado. La cristalización es seguida de un secado llevado a cabo bajo condiciones controladas hasta alcanzar un contenido de agua específico en el producto final.
ARP110102193A 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS AR081991A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
AR081991A2 true AR081991A2 (es) 2012-10-31

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Country Status (38)

Country Link
US (5) US7045620B2 (es)
EP (6) EP1557421B1 (es)
JP (5) JP2005139161A (es)
KR (4) KR20050043589A (es)
CN (4) CN1613858A (es)
AR (3) AR043547A1 (es)
AT (3) ATE361927T1 (es)
AU (2) AU2004200964A1 (es)
BR (2) BRPI0402382A (es)
CA (2) CA2460384A1 (es)
CL (1) CL2004000498A1 (es)
CO (1) CO5560083A1 (es)
CY (3) CY1108017T1 (es)
DE (4) DE602004006367C5 (es)
DK (3) DK1676848T3 (es)
ES (3) ES2320161T3 (es)
HK (3) HK1092150A1 (es)
HR (2) HRP20040265A2 (es)
IL (2) IL160798A0 (es)
IT (1) ITMI20032144A1 (es)
JO (1) JO2470B1 (es)
MA (1) MA27069A1 (es)
MD (1) MD3653G8 (es)
ME (1) ME00424B (es)
MX (2) MXPA04002353A (es)
NO (1) NO334950B1 (es)
NZ (1) NZ531622A (es)
PL (3) PL1676848T3 (es)
PT (3) PT1557421E (es)
RS (4) RS54569B1 (es)
RU (1) RU2270200C2 (es)
SI (3) SI1557421T1 (es)
TN (2) TNSN04044A1 (es)
TW (1) TWI285107B (es)
UA (1) UA86384C2 (es)
WO (1) WO2005044823A2 (es)
YU (1) YU24804A (es)
ZA (1) ZA200401948B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CN104382900A (zh) 2006-08-02 2015-03-04 萨利克斯药品公司 治疗放射性肠炎的组合物和方法
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) * 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
UA101829C2 (uk) * 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
PL2252148T3 (pl) * 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Sposoby leczenia zespołu jelita drażliwego
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
EP3964066A1 (en) 2009-06-02 2022-03-09 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）の治療方法
MX346660B (es) * 2009-10-27 2017-03-28 Lupin Ltd Dispersion solida de rifaximina.
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
US8952159B2 (en) † 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
WO2011103246A1 (en) 2010-02-18 2011-08-25 Salix Pharmaceuticals, Ltd. Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
BR112012030783A2 (pt) * 2010-06-03 2015-09-29 Salix Pharmaceuticals Ltd formas de rifaximina e seus usos
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
WO2012009388A1 (en) * 2010-07-12 2012-01-19 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
CA2825964A1 (en) * 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
WO2013067394A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
ES2829285T3 (es) 2013-04-12 2021-05-31 Alfasigma Spa Administración de AINE y composiciones, métodos y sistemas relacionados
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
EP3373914B2 (en) 2016-03-24 2022-06-01 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
CA3013161C (en) * 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
PL3645539T3 (pl) 2017-06-26 2021-10-25 Biofer S.P.A. Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
AU2020355603A1 (en) 2019-09-24 2022-03-17 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
UA101829C2 (uk) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ

Also Published As

Publication number Publication date
EP1682556A2 (en) 2006-07-26
DE602004006367T2 (de) 2007-09-06
BRPI0407149A (pt) 2006-02-07
DE602004006367C5 (de) 2019-04-04
KR100867751B1 (ko) 2008-11-10
RU2270200C2 (ru) 2006-02-20
CY1108909T1 (el) 2014-07-02
WO2005044823A2 (en) 2005-05-19
ES2244364T3 (es) 2007-12-01
DE602004019298D1 (de) 2009-03-19
CN101260114A (zh) 2008-09-10
CA2538546C (en) 2011-04-19
CA2460384A1 (en) 2005-05-07
JO2470B1 (en) 2009-01-20
DK1676848T3 (da) 2009-05-11
DE602004019296D1 (de) 2009-03-19
BRPI0402382A (pt) 2005-06-28
YU24804A (sh) 2006-08-17
EP1676848A1 (en) 2006-07-05
HRP20060093B1 (hr) 2015-12-18
NZ531622A (en) 2004-10-29
HRP20060093A2 (en) 2006-05-31
ES2320161T3 (es) 2009-05-19
CN101260114B (zh) 2012-11-28
ES2320160T4 (es) 2011-03-09
AR081992A2 (es) 2012-10-31
US20050272754A1 (en) 2005-12-08
EP2210893A1 (en) 2010-07-28
ATE421966T1 (de) 2009-02-15
KR100855084B1 (ko) 2008-08-29
IL174271A (en) 2010-12-30
JP5635376B2 (ja) 2014-12-03
JP2011057698A (ja) 2011-03-24
MXPA06002644A (es) 2006-06-06
EP1676848B1 (en) 2009-01-28
MXPA04002353A (es) 2005-05-11
SI1676848T1 (sl) 2009-06-30
RS20150291A1 (en) 2015-10-30
EP1676847A1 (en) 2006-07-05
MD3653F2 (en) 2008-07-31
PT1676847E (pt) 2009-04-09
DK1676847T3 (da) 2009-05-11
JP2007509904A (ja) 2007-04-19
US7915275B2 (en) 2011-03-29
US20050101598A1 (en) 2005-05-12
AU2004200964A1 (en) 2005-05-26
US8404704B2 (en) 2013-03-26
PT1557421E (pt) 2007-07-31
US8173801B2 (en) 2012-05-08
SI1676847T1 (sl) 2009-06-30
ATE361927T1 (de) 2007-06-15
MA27069A1 (fr) 2004-12-20
RS54568B1 (en) 2016-06-30
DK1557421T3 (da) 2007-09-17
RS54569B1 (en) 2016-06-30
CA2538546A1 (en) 2005-05-19
ME00424B (me) 2011-10-10
DE602004006367D1 (de) 2007-06-21
ITMI20032144A1 (it) 2005-05-08
CL2004000498A1 (es) 2005-03-11
EP1676847B1 (en) 2009-01-28
KR20070113327A (ko) 2007-11-28
CN1613858A (zh) 2005-05-11
JP2011046738A (ja) 2011-03-10
CN1886408B (zh) 2010-06-09
US20110160449A1 (en) 2011-06-30
IL174271A0 (en) 2006-08-01
SI1557421T1 (sl) 2007-08-31
JP5199576B2 (ja) 2013-05-15
PT1676848E (pt) 2009-04-09
CN101260115A (zh) 2008-09-10
HK1073657A1 (en) 2005-10-14
KR20060110737A (ko) 2006-10-25
CO5560083A1 (es) 2005-09-30
CY1108017T1 (el) 2013-09-04
HK1092151A1 (en) 2007-02-02
AU2004287601A1 (en) 2005-05-19
DE04005541T1 (de) 2005-12-29
PL1676847T3 (pl) 2009-07-31
UA86384C2 (uk) 2009-04-27
EP2208730A1 (en) 2010-07-21
KR100883216B1 (ko) 2009-02-13
US7045620B2 (en) 2006-05-16
KR20050043589A (ko) 2005-05-11
CY1108964T1 (el) 2014-07-02
TNSN04044A1 (en) 2006-06-01
IL160798A0 (en) 2004-08-31
TNSN06069A1 (en) 2007-10-03
RS20150292A1 (en) 2015-10-30
HK1092150A1 (en) 2007-02-02
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
RS20060168A (en) 2008-09-29
MD3653G8 (ro) 2016-08-31
TWI285107B (en) 2007-08-11
CN1886408A (zh) 2006-12-27
BRPI0407149A8 (pt) 2019-01-15
NO334950B1 (no) 2014-08-04
ZA200401948B (en) 2004-04-29
RU2004108953A (ru) 2005-10-27
EP1557421B1 (en) 2007-05-09
US20080132530A1 (en) 2008-06-05
RS54571B1 (en) 2016-06-30
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
KR20070113326A (ko) 2007-11-28
TW200515913A (en) 2005-05-16
NO20061110L (no) 2006-04-19
JP2005139161A (ja) 2005-06-02
AU2004287601B8 (en) 2009-03-05
ES2244364T1 (es) 2005-12-16
JP2014177500A (ja) 2014-09-25
CN101260115B (zh) 2011-11-23
AU2004287601B2 (en) 2009-02-26
PL1557421T3 (pl) 2007-08-31
MD20060080A (en) 2006-11-30
US20120059023A1 (en) 2012-03-08
ATE421965T1 (de) 2009-02-15
EP1557421A1 (en) 2005-07-27
AR043547A1 (es) 2005-08-03

Similar Documents

Publication Publication Date Title
AR081991A2 (es) FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
MD4081F2 (en) Polymorphous forms of rifaximin, processes for their production and use as medicinal preparations with antibiotic action
JO2793B1 (en) The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
UA83718C2 (ru) Кристаллическая форма iv агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
DE602004021959D1 (de) Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
TN2009000030A1 (en) Use of polyols to obtain stable polymorphous forms of rifaximin
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
SI2125850T1 (en) MACROCYCLIC POLYMORPHOSES, INSTALLATIONS INCLUDING SUCH POLYMORPHES, METHODS OF MANUFACTURE AND USE OF OTHERS
EP2641897A3 (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof
UA94395C2 (ru) Производное изоксазолина и способ его получения
NO20076138L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
MX2007001267A (es) Derivados de naftiridinas 2,8-disustituidas.
HRP20240026T1 (hr) Kruti oblik ribociklib sukcinata
WO2008021235A3 (en) Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives
EP2215070A4 (en) NEW 1,3-DIHYDRO-5-ISOBENZOFURANCARA ACID ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION
MX2016013039A (es) Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia.
BG107407A (en) Novel polymorph v of torasemide
DE50006842D1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
AR058282A1 (es) Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
EP1556364A4 (en) ISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES
TW200509889A (en) Aniline derivatives
GEP20094652B (en) New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
FC Refusal